Siddiqi, Shan H.
Kandala, Sridhar
Hacker, Carl D.
Trapp, Nicholas T.
Leuthardt, Eric C.
Carter, Alexandre R.
Brody, David L.
Funding for this research was provided by:
McDonnell Center for Systems Neuroscience
Article History
Received: 1 October 2021
Accepted: 5 October 2022
First Online: 11 March 2023
Competing interests
: SHS serves as a scientific consultant for Magnus Medical and a clinical consultant for Kaizen Brain Center and Acacia Mental Health. SHS has received research support from Neuronetics Inc and Brainsway Ltd. SHS owns shares in Brainsway Ltd (publicly-traded) and Magnus Medical (not publicly traded). SHS has served as an speaker on behalf of Otsuka (unbranded educational material) and Brainsway (unbranded scientific material). None of these entities were involved in the present work. DLB has served as a consultant for Pfizer Inc, Intellectual Ventures, Signum Nutralogix, Kypha Inc, Sage Therapeutics, iPerian Inc, Navigant, Avid Radiopharmaceuticals (Eli Lilly & Co), the St Louis County Public Defender, the United States Attorney’s Office, the St Louis County Medical Examiner, GLG, Stemedica, Luna Innovations, and QualWorld. DLB holds equity in the company Inner Cosmos. DLB receives royalties from sales of Concussion Care Manual (Oxford University Press) and an honorarium from Mary Ann Liebert Inc for services as Editor-in-Chief of <i>Journal of Neurotrauma</i>. No conflicts of interest with the presented work. DLB is an employee of the Department of Defense; the views expressed here do not reflect those of the Uniformed Services University of the Health Sciences, the US Department of Defense, or the US Government. ECL holds equity in the companies Neurolutions and Inner Cosmos. CDH, ECL, and SHS hold intellectual property related to the use of RSNM to target TMS. The remaining authors report no conflicts of interest.